Medicine Recommendations

Rheumatoid arthritis (LSCMMG pathway)

Juvenile Idiopathic Arthritis (JIA) in Adult Patients  

Treatment of pain in knee osteoarthritis and plantar fasciitis

Rheumatoid arthritis (LSCMMG pathway)

Second line in Psoriatic Arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy

Ankylosing spondylitis (NICE TA383)

NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

Juvenile Idiopathic Arthritis (JIA) in Adult Patients

Non-radiographic axial spondyloarthritis (NICE TA383)

NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

Psoriatic arthritis (NICE TA199)

NICE TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis

Gout (as per LSCMMG Guidelines)

Rheumatoid arthritis (CG79)

NICE CG79 - Rheumatoid arthritis: The management of rheumatoid arthritis in adults

Active Psoriatic Arthritis (NICE TA433)

NICE TA433 - Apremilast for treating Active Psoriatic Arthritis

Inflammatory bowel disease, Rheumatic diseases, Dermatology

Rheumatoid arthritis (LSCMMG pathway)

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Active psoriatic arthritis (NICE TA916)

NICE TA916 - Bimekizumab for treating active psoriatic arthritis

Axial spondyloarthritis (NICE TA918)

NICE TA918 - Bimekizumab for treating axial spondyloarthritis

Gouty arthritis (NICE TA 281 - terminated appraisal)

NICE TA281 - Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal)

Juvenile idiopathic arthritis (systemic) (NICE TA302)

NICE TA302 - Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)

For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication.

This recommendation only covers the use of Delta-9-Tetrahydrocannabinol (THC) 27mg and Cannabidiol (CBD) 25mg (Sativex) oromucosal spray for the indication of moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication

Cannabis-based medicinal products NG144

Cannabis-Based Products for the management of patients with chronic pain

Cannabis-based medicinal products NG144